EMA’s PRAC Requests Additional Data on Guillain-Barré Syndrome in COVID-19 Vaccine

EMA’s Pharmacovigilance Risk Assessment Committee has requested more data for its evaluation of reports of Guillain-Barré syndrome after vaccination.